Data from EMA (European Medicines Agency) - Curated by EPG Health - Last updated 07 November 2017

Indication(s)

Prevention of delayed nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults.

Varuby is given as part of combination therapy.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Fluid Management

Fluid Management

Are you up-to-date with the latest evidence of effective procedures for fluid management?

+ 2 more

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more

Biosimilars in Oncology Knowledge Centre

Biosimilars in Oncology Knowledge Centre

What are biologics and how do they differ from small molecule medicines? Discover more about their development, as well as the manufacturing and regulatory processes in the Biosimilars in Oncology Knowledge Centre.

Load more

Related Content

More information

Category Value
Agency product number EMEA/H/C/004196
Orphan designation No
Date First Approved 20-04-2017
Type Medicinal product subject to medical prescription
Marketing authorisation holder Tesaro UK Limited